{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:27:16Z","timestamp":1794328036254,"version":"4.9.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Optimal treatment in patients with refractory or relapsed peripheral T-cell lymphomas (R\/R\u00a0T-NHLs) is unknown. In this population-based study, outcomes in R\/R peripheral T-cell lymphoma not otherwise specified (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase-positive (ALK+) and ALK-negative (ALK\u2013) anaplastic large cell lymphoma (ALCL) were evaluated. Patients with PTCL NOS, AITL, ALK+ ALCL, and ALK\u2013 ALCL (\u226518 years) diagnosed in 2014 to 2019 were identified using the Netherlands Cancer Registry. End points were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The 2-year PFS of 821 patients was 57%. Among 311 patients with a relapse, 243 received second-line treatment: 44% received salvage chemotherapy, 20% received brentuximab vedotin (BV), and 36% received other treatment. In third-line treatment, BV was most commonly used (38%). ORR after second-line treatment was 47%. Two-year PFS and OS after relapse were 25% and 34%, respectively. The risk of second relapse was negatively affected by early relapse (&amp;lt;12\u00a0months after diagnosis), whereas BV reduced this risk compared with salvage chemotherapy. Reduced risk of relapse was independent of histological subtype. The best outcomes were observed for patients treated with salvage chemotherapy receiving consolidative autologous and allogeneic stem cell transplantation (SCT) (2-year OS 68%), patients treated with BV achieving a second complete remission (2-year OS 74%) and patients with allogeneic SCT (2-year OS 60%). The risk of second relapse was significantly lower for patients with R\/R T-NHL treated with BV compared with patients treated with salvage chemotherapy, and this was irrespective of subtype. Therefore, the use of salvage chemotherapy for patients with R\/R T-NHL is challenged.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012531","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T18:03:58Z","timestamp":1715623438000},"page":"3619-3628","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-4810","authenticated-orcid":false,"given":"Mirian","family":"Brink","sequence":"first","affiliation":[{"name":"1Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francien","family":"Huisman","sequence":"additional","affiliation":[{"name":"2Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"3Department of Hematology, Treant Hospital, Emmen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik O.","family":"Meeuwes","sequence":"additional","affiliation":[{"name":"2Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"3Department of Hematology, Treant Hospital, Emmen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein W. M.","family":"van der Poel","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Interne Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle","family":"Wondergem","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"B\u00f6hmer","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Haga Hospital, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-6156","authenticated-orcid":false,"given":"F. J. Sherida H.","family":"Woei-A-Jin","sequence":"additional","affiliation":[{"name":"7Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Isala Hospital, Zwolle, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3650-4588","authenticated-orcid":false,"given":"Rimke","family":"Oostvogels","sequence":"additional","affiliation":[{"name":"9Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty M.","family":"Jansen","sequence":"additional","affiliation":[{"name":"10Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[{"name":"11Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd J. F.","family":"Snijders","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Medisch Spectrum Twente, Enschede, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[{"name":"2Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1628-6256","authenticated-orcid":false,"given":"Joost S. P.","family":"Vermaat","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9828-9460","authenticated-orcid":false,"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[{"name":"2Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[{"name":"2Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"2024072313012780500_bib1","unstructured":"Integraal Kankercentrum Nederland. Accessed 15 October 2023. www.iknl.nl."},{"issue":"18","key":"2024072313012780500_bib2","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"10168","key":"2024072313012780500_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"2024072313012780500_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2024072313012780500_bib5","first-page":"2646","article-title":"A\u00a0randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"27","key":"2024072313012780500_bib6","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024072313012780500_bib7","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2024072313012780500_bib8","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A\u00a0phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"1","key":"2024072313012780500_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024072313012780500_bib10","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta, gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024072313012780500_bib11","doi-asserted-by":"crossref","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"2024072313012780500_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024072313012780500_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann Hematol"},{"issue":"18","key":"2024072313012780500_bib14","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2024072313012780500_bib15","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2024072313012780500_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41409-019-0732-9","article-title":"Allogeneic hematopoietic stem cell transplantation for patients with relapsed\/refractory systemic anaplastic large cell lymphoma. a retrospective analysis of the lymphoma working party of the European Society for Blood and Marrow Transplantation","volume":"55","author":"Domingo-Domenech","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024072313012780500_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the societe francophone de greffe de moelle et de therapie cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"16","key":"2024072313012780500_bib18","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024072313012780500_bib19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"2024072313012780500_bib20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"issue":"27","key":"2024072313012780500_bib21","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024072313012780500_bib22","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"28","key":"2024072313012780500_bib23","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2024072313012780500_bib24","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2024072313012780500_bib25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024072313012780500_bib26","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2022-165217","article-title":"Addition of brentuximab vedotin to gemcitabine in relapsed or refractory T-cell lymphoma: final analysis of a LYSA multicenter, phase II study. \u201cthe TOTAL trial\u201d","volume":"140","author":"Tournilhac","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2024072313012780500_bib27","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1182\/bloodadvances.2022008524","article-title":"Salvage therapy with brentuximab-vedotin and bendamustine for patients with R\/R PTCL: a retrospective study from the LYSA group","volume":"7","author":"Aubrais","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024072313012780500_bib28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A\u00a0phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2024072313012780500_bib29","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"issue":"18","key":"2024072313012780500_bib30","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3619\/2235630\/blooda_adv-2023-012531-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3619\/2235630\/blooda_adv-2023-012531-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T13:25:26Z","timestamp":1721741126000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/14\/3619\/516082\/Treatment-strategies-and-outcome-in-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012531","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]}}}